Erasca (ERAS) is under pressure after multiple law firms launched class action lawsuits and a securities fraud investigation tied to alleged misstatements about ERAS-0015 data, potential patent issues, and a reported patient death.

Despite the legal headlines, Erasca’s 1 month share price return of 41.06% and year to date share price return above 300% have put the stock in sharp focus. The 1 year total shareholder return is very large, pointing to strong recent momentum that contrasts with the ongoing class action and investigation over ERAS-0015.

If you are reassessing risk and reward after Erasca’s legal shocks, it may help to broaden your watchlist and scan 39 healthcare AI stocks

With Erasca now valued at about US$4.4b, no current revenue, reported annual net losses and a recent share price surge, you have to ask: is the legal risk fully reflected, or is the market already pricing in future growth potential?

Preferred Price to Book of 11.4x: Is It Justified?

Erasca trades on a P/B of 11.4x, which sits well above the wider US Biotechs industry but below the average for its closer peer group.

P/B compares the company’s market value to its net assets on the balance sheet. This matters here because Erasca is a clinical stage business with no current revenue and reported net losses of $277.02m.

At this level, the market is placing a high value on the company’s pipeline and future revenue potential. This is occurring even though analysts also expect Erasca to remain unprofitable over the next 3 years and the stock carries a Simply Wall St value score of 1 out of 6.

Compared with the broader US Biotechs industry average P/B of 2.4x, Erasca’s 11.4x looks very expensive. However, relative to a peer average of 26.2x it screens as cheaper, which highlights how much expectations can vary inside high growth, loss making biotech.

Result: Price to book of 11.4x (OVERVALUED).

However, legal uncertainty around ERAS-0015 and ongoing net losses of US$277.02m could quickly challenge confidence if trial outcomes or funding conditions disappoint.

Next Steps

With sentiment clearly split between sharp share price gains and serious legal and financial questions, it makes sense to move quickly and review the full picture for yourself. To weigh up both sides of the story in one place, start with the 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If Erasca’s sharp moves have your attention, do not stop here. Expand your opportunity set by scanning focused stock lists built around specific strengths and traits.

• Spot potential turnaround stories early by checking out 23 elite penny stocks with strong financials that already show stronger financial footing than many tiny peers.
• Target quality at a reasonable price by reviewing the 47 high quality undervalued stocks that combine fundamentals with room for sentiment to improve.
• Prioritise resilience and sleep better at night by screening for 68 resilient stocks with low risk scores that aim to limit unpleasant surprises in your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.